PELLEGATTA, SERENA
PELLEGATTA, SERENA
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE (attivo dal 01/01/1998 al 30/09/2012)
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma
2014 Favaro, R; Appolloni, I; Pellegatta, S; Sanga, A; Pagella, P; Gambini, E; Pisati, F; Ottolenghi, S; Foti, M; Finocchiaro, G; Malatesta, P; Nicolis, S
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
2015 Pellegatta, S; Valletta, L; Corbetta, C; Patane', M; Zucca, I; Riccardi Sirtori, F; Bruzzone, M; Fogliatto, G; Isacchi, A; Pollo, B; Finocchiaro, G
Hypermutations in gliomas: A potential immunotherapy target
2017 Finocchiaro, G; Langella, T; Corbetta, C; Pellegatta, S
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
2018 Pellegatta, S; Savoldo, B; Di Ianni, N; Corbetta, C; Chen, Y; Patané, M; Sun, C; Pollo, B; Ferrone, S; Dimeco, F; Finocchiaro, G; Dotti, G
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+T cell activation in the presence of adjuvant temozolomide
2018 Pellegatta, S; Eoli, M; Cuccarini, V; Anghileri, E; Pollo, B; Pessina, S; Frigerio, S; Servida, M; Cuppini, L; Antozzi, C; Cuzzubbo, S; Corbetta, C; Paterra, R; Acerbi, F; Ferroli, P; Dimeco, F; Fariselli, L; Parati, E; Bruzzone, M; Finocchiaro, G
Altered function of the glutamate–aspartate transporter GLAST, a potential therapeutic target in glioblastoma
2019 Corbetta, C; Di Ianni, N; Bruzzone, M; Patanè, M; Pollo, B; Cantini, G; Cominelli, M; Zucca, I; Pisati, F; Poliani, P; Finocchiaro, G; Pellegatta, S